Anthonie J. van der Wekken

Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text

Medicine, Oncology, Pharmacology +15

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 566 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Frank Griesinger, Giuseppe Curigliano, Michael Thomas et al. · Annals of Oncology · 2022 · 178 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

Justine L. Kuiper, Lizza Hendriks, Anthonie J. van der Wekken et al. · Lung Cancer · 2015 · 135 citations · Full text

Medicine, Oncology, Metastasis +15